Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Apr 16, 2023 2:03pm
174 Views
Post# 35397443

RE:RE:Merck to buy Prometheus Bio....

RE:RE:Merck to buy Prometheus Bio....Venture009,

With respect, you stringing together disappointments and lumping things together that do not make sense.

The sample sizes of all our trials are driven by cost and the difficulty of getting participants, as well as the purpose of the trials at that stage. The sample sizes were set large enough to accomplish the purposes of the trials, and approved by regulators. Even with large sample sizes we are still doing sampling and statistical tests, which themselves have developed as a sort of a standard but still do not  bring certainty about success in treating cancer. Nothing is a sure thing. However adverse side effects (even perhaps death) from all stanard chemo and rad treatments ARE a sure thing. We have no adverse side effects worth mentioning. 

The H and N trial was run in strange ways (Brad was in charge), involved tossing out lots of subjects who had fevers, and ultimately ONCY was told by the FDA to split the samples, learn from the experience and come back in the future.

This BS about there being some fatal flaw in pela is just that, BS. There is no evidence. to that effect. The results of last fall and the last few years working with i/o combos belies the idea that there is some hidden reason that big pharma does not want us. Uber on Yahoo says that Pfizer passed on ONCY 20 years ago, so why would they want us now? The answer is: I/O emergence and our results. 
<< Previous
Bullboard Posts
Next >>